What is HC Wainwright’s Estimate for EPRX Q2 Earnings?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Eupraxia Pharmaceuticals in a research note issued on Thursday, June 26th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.29) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02).

Separately, Canaccord Genuity Group assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a “speculative buy” rating on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $11.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $5.76 on Monday. Eupraxia Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $5.90. The company’s 50 day moving average price is $4.05 and its 200-day moving average price is $3.59. The stock has a market capitalization of $207.13 million, a price-to-earnings ratio of -7.58 and a beta of 0.66.

Institutional Trading of Eupraxia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in EPRX. Royal Bank of Canada lifted its position in shares of Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares during the period. Scotia Capital Inc. lifted its holdings in Eupraxia Pharmaceuticals by 11.6% in the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock worth $5,072,000 after buying an additional 160,960 shares during the period. Millennium Management LLC purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $31,000. Raymond James Financial Inc. bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Bank of Montreal Can grew its holdings in shares of Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after acquiring an additional 7,500 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.